Colony stimulating factor-1 (CSF1) and its receptor (CSF1-R) are important in mammary gland development and have been implicated in breast carcinogenesis. In a nested case-control study in the Nurses' Heath Study of 726 breast cancer cases diagnosed between June 1, 1992, and June 1, 1998, and 734 matched controls, we prospectively evaluated whether circulating levels of CSF1 (assessed in 1989-1990) are associated with breast cancer risk. The association varied by menopausal status (P heterogeneity = 0.009). CSF1 levels in the highest quartile (versus lowest) were associated with an 85% reduced risk of premenopausal breast cancer [relative risk (RR), 0.15; 95% confidence interval (95% CI), 0.03-0.85; P trend = 0.02]. In contrast, CSF1 levels in the highest quartile conferred a 33% increased risk of postmenopausal breast cancer (RR, 1.33; 95% CI, 0.96-1.86; P trend = 0.11), with greatest risk for invasive (RR, 1.45; 95% CI, 1.02-2.07; P trend = 0.06) and ER+/PR+ tumors (RR, 1.72; 95% CI, 1.11-2.66; P trend = 0.04). Thus, the association of circulating CSF1 levels and breast cancer varies by menopausal status. [Cancer Res 2008;68(1):18-21] 
Introduction
Macrophage colony-stimulating factor (CSF1), originally identified as a hematopoietic growth factor, stimulates proliferation, differentiation, and survival of monocytes and macrophages (1) . More recently, CSF1 and its receptor (CSF1R) have exhibited an important role in mammary gland development (2, 3) and are implicated in breast and ovarian carcinogenesis (3) . Many cell types, including epithelial and mesenchymal cells and osteoblasts, produce CSF1 (4) . Although expressed at low levels in normal resting breast epithelium (5), CSF1 is expressed at high levels in the mammary gland during pregnancy and lactation and in breast tumors (6) (7) (8) .
The proliferative effects of CSF1 are mediated by its binding to CSF1R and the induction of signal transduction pathways. Autocrine CSF1R activation induces hyperproliferation and loss of basement membrane integrity in human mammary epithelial cells (9) . Levels of circulating CSF1 are higher in patients with ovarian, breast, and endometrial cancer than in healthy individuals (8, 10) . CSF1 expression in breast tumors also correlates with grade and progression (3, 8) . No studies of prospectively measured levels of circulating CSF1, and subsequent risk of breast cancer have been published. Thus, it is unclear whether circulating CSF1 is a tumor marker for breast cancer or predictive of breast cancer risk. We conducted a study within the Nurses' Health Study to determine whether circulating levels of CSF1 predict breast cancer risk. (12) , one control was excluded with a CSF1 value of 2,654.1 pg/mL.
Materials and Methods
Statistical analysis. We used conditional and unconditional logistic regression models to estimate the relative risk (RR) of breast cancer, with 95% CI adjusted for known risk factors. Quartiles of circulating CSF1 were based on the distribution among controls. In analyses stratified by menopausal status, categories were based on premenopausal and postmenopausal distributions separately. The simple conditional model was based on 725 matched case control pairs with circulating CSF1 data. Multivariate models were adjusted for prior benign breast disease (yes/no), BMI at age 18 years (continuous), weight gain (<5, 5-<20, 20+, and missing), parity/age at first birth (nulliparous; para 1-2, first birth V 24; para 1-2, first birth after 24; para 3+, first birth V24; and para 3+, first birth after 24), alcohol (none, <3 drinks/wk, 3-6 drinks/wk, and 7-13 drinks/wk), family history of breast cancer (yes/no), age at menarche (<12, 12, 13, >13), age at menopause (V45, 46-50, 51+), and duration of PMH use (premenopausal, never, past <60, past 60+, current <60, current 60+). Menopausal status and use of PMHs at blood collection were assessed through a supplemental questionnaire given at that time. All other covariates were assessed from biennial questionnaires. Tests for trend were based on the Wald test when the log-transformed continuous measure of circulating CSF1 was included as an independent variable. Polytomous logistic regression (13) was used to test for differences in trend across CSF1 levels according to ER+/PR+ to ERÀ/PRÀ tumors. There were too few cases of ERÀ/PR+ breast cancers for these groups to be considered separately. 
Results and Discussion
Mean circulating levels of CSF1 were similar for cases (584.7 pg/ mL; range, 163.1-2,170.5 pg/mL) and controls (583.7 pg/mL; range 169.7-2,078.7 pg/mL). Among controls, circulating CSF1 was positively associated with BMI and weight gain since age 18 years and inversely associated with alcohol consumption (Table 1) . Women with the highest levels of circulating CSF1 were more likely to be postmenopausal, have a family history of breast cancer, and be parous than women with lower levels.
Overall, circulating CSF1 levels and risk of breast cancer (P trend = 0.37; Table 2 ) were not associated. However, the association varied by menopausal status (P heterogeneity = 0.009). Women with CSF1 levels in the highest (versus lowest) quartile had an 85% reduced risk of premenopausal breast cancer (RR, 0.15; 95% CI, 0.03-0.85; P trend = 0.02) and a contrasting nonsignificant 33% increased risk of postmenopausal breast cancer (RR, 1.33; 95% CI, 0.96-1.86; P trend = 0.11). The association between CSF1 and postmenopausal breast cancer seemed stronger when limited to invasive cancers (RR, 1.45; 95% CI, 1.02-2.07; P trend = 0.06; Table 3 ). CSF1 was associated with ER+/PR+ breast cancers (RR, 1.72; 95% CI, 1.11-2.66; Table 3 ) but not ERÀ/PRÀ tumors (RR, 0.70; 95% CI, 0.34-1.44; P heterogeneity = 0.03; Table 3 ).
Because we observed a strong positive association between circulating CSF1 with both weight gain since age 18 years and current BMI (Table 1) , and adiposity is a risk factor for breast cancer, we also ran multivariate models adjusted for both weight gain since age 18 years and current BMI (continuous). The results were essentially unchanged from those presented in Tables 2  and 3 .
To understand the divergence of associations by menopausal status, we conducted stratified analyses among postmenopausal women with higher estrogen environments. However, the CSF1-breast cancer association was not modified by PMH use (P heterogeneity = 0.68) or BMI (P heterogeneity = 0.29).
To our knowledge, this is the first prospective study to examine circulating levels of CSF1 and subsequent risk of breast cancer. CSF1 was inversely related to premenopausal and positively associated with postmenopausal breast cancer. Although a priori we would not have predicted differential effects for CSF1 by menopausal status, the association of other exposures (e.g., BMI and circulating insulin-like growth factor levels) with breast cancer depends on menopausal status. The mechanism by which CSF1 may differentially influence premenopausal and postmenopausal breast cancer risk is unclear. Additional studies in premenopausal women are necessary to confirm these results.
One study suggests that CSF1 can influence breast cell proliferation either positively or negatively, depending on the estrogen environment (14) . In ER+ cell lines, estradiol induced a 3-to 5-fold increase in growth, whereas CSF1 alone did not (14) . However, in combination, CSF1 inhibited the proliferative effects of estradiol by inducing G 1 arrest. In contrast, earlier work in ER cell lines showed that CSF1 induced proliferation (15, 16) . These data suggest that in a high-estrogen environment, CSF1 inhibits proliferative effects of mitogens such as estradiol.
Accumulating evidence supports a role for CSF1 in breast carcinogenesis. Activation of CSF1R causes uncontrolled growth (9) , increases the invasive potential of epithelial cells (17) , and promotes angiogenesis (18) . In animal models, blockade of CSF1 through antisense oligonucleotides or neutralizing anti-CSF1 antibodies suppressed tumor growth and prolonged long-term survival (19, 20) . Thus, CSF1R may be a target for breast cancer chemoprevention. This initial prospective study of circulating CSF1 levels suggests that CSF1 is a biomarker of subsequent postmenopausal breast cancer risk. Additional studies will be necessary to replicate these findings. This study was limited by the number of premenopausal breast cancer cases; it remains to be seen whether CSF1 has disparate effects in premenopausal and postmenopausal women.
